about
Response to chemotherapy is not related to chromosome instability in synovial sarcoma.Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.Role of geriatric intervention in the treatment of older patients with cancer: rationale and design of a phase III multicenter trial.Immune checkpoint inhibitors and elderly people: A review.Targeted therapy and elderly people: A review.Efficacy and tolerance of everolimus in 123 consecutive advanced ER positive, HER2 negative breast cancer patients. A two center retrospective study.Functional decline in older patients with cancer receiving first-line chemotherapy.Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-study of EORTC 10994/BIG 1-00 phase III trial.Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors.Genomic complexity in pediatric synovial sarcomas (Synobio study): the European pediatric soft tissue sarcoma group (EpSSG) experience.Dynamic contrast enhanced MRI-derived parameters are potential biomarkers of therapeutic response in bladder carcinoma.[Hepatotoxicity of tyrosine kinase inhibitors: Mechanisms involved and practical implications].[Genomic signature of breast cancer: The quest for the Holy Grail]Encouraging Trends in Modern Phase 1 Oncology Trials
P50
Q34395325-9888F7EB-6C23-47FC-B700-EC943FA4E374Q35005762-28CE7C46-B3C3-47D4-B37E-4930483978B4Q36210646-B38A09D0-A7FD-4569-A916-ABBB964052DFQ38688111-5EEF3BC1-9A77-4C9A-AB31-DE978A16A894Q39010838-C81502DF-7F6D-4157-9685-3E739DDF7156Q40521369-FC0E8254-0AB4-440D-9993-2BE7EE9CA368Q45742864-F7824D0F-F101-401B-90F7-74213412E79FQ47412964-92844218-90F9-4025-A98C-BFBAD6A23989Q47736062-44BBB65F-9A43-444C-830D-053ABEFB0890Q52357735-B7510AF3-A2C0-4BA8-9F71-A3B073F71B32Q53574597-D247BE43-FB11-434C-8DDF-1E2E7F486062Q54124952-A3B96782-0EAF-4AC8-8D79-E2FE7A8459B3Q85484175-F6453DFD-07CF-4823-BE2F-57900CB4E77DQ89010921-6484C367-114E-4D3F-BEEC-7E01ED4C8468
P50
description
researcher, ORCID id # 0000-0002-6383-9589
@en
wetenschapper
@nl
name
C Chakiba
@ast
C Chakiba
@en
C Chakiba
@nl
type
label
C Chakiba
@ast
C Chakiba
@en
C Chakiba
@nl
prefLabel
C Chakiba
@ast
C Chakiba
@en
C Chakiba
@nl
P106
P31
P496
0000-0002-6383-9589